Interventional Cardiology Resource Center Editorial Programs

 
 
  • Mandrola Previews 2018 ACC PCSK9 inhibitors, LifeVest, and his-bundle pacing are among Dr Mandrola's picks for what to look for at the 2018 American College of Cardiology Scientific Sessions.
  • The Rise and Fall of BVS and the FDA Device-Approval Process   Drs Mandrola and Kaul reflect on the less-than-stellar results for the first-generation bioresorbable stent and discuss the challenges of balancing innovation and safety in the device-approval process.
  • 7 Cardiology Trials to Look for in 2018   Trials on PCSK9 inhibitors, antiplatelets, anticoagulants, and even catheter ablation of atrial fibrillation are among Drs Harrington and Gibson's picks for what to look for in 2018.
  • Insights for the Next Generation of Women in Medicine In honor of National Women Physicians Day, we've collated insights from trailblazers in cardiology that may smooth the path for the next generation of women who enter male-dominated fields.
  • Public Reporting as Public Shaming, and Potential Solutions   A recent viewpoint by Dr Bhatt against public reporting of PCI outcomes garnered a lot of support in the cardiology community and beyond. Dr Harrington asks how it can be done better.
  • Life and Times of Leading Cardiologists: Gilles Montalescot   Magnus Ohman speaks with Gilles Montalescot, whose illustrious career in cardiology and research in thrombosis led him from Paris to Beacon Hill and back.
  • How Did We End Up With so Many Medical Journals?   Dr DeMaria discusses his tenure at JACC, the proliferation of cardiology journals, and his current projects.
  • In Defense of Less-Is-More Cardiologist and New England Journal of Medicine correspondent, Lisa Rosenbaum, MD recently critiqued the less-is-more in medicine crusaders. One such crusader, Dr Mandrola, respectfully disagrees.
  • What COMPASS and RE-DUAL Mean for Aspirin and Triple Therapy   Drs Cohen and O'Donoghue review new data from the COMPASS and RE-DUAL PCI trials and potential strategies for patients who need anticoagulation and antiplatelet therapy.
  • The Top Cardiology Trials of 2017 in Review   In this annual tradition, Drs Harrington and Gibson discuss their picks for the top cardiology trials of the year, covering PCSK9 inhibitors, anti-inflammatory and anthithrombotic drugs, and PCI.
  • Mandrola's Top 10 Cardiology Stories of 2017 Controversy surrounding saturated fat and sham PCI make this year's list as well as a few medical reversals and the continuing opioid crisis. What topics would you add or omit?
  • ORBITA: Sham PCI Trial Sends Stents and CardioTwitter Reeling What are the biggest misperceptions about the trial that inspired 1700+ tweets in 9 days? And why did it send US interventional cardiologists into a tizzy while their UK counterparts remained calm?
  • DAPT Dilemmas Endure While BMS Should Fade Away   Dual antiplatelet therapy duration after coronary stenting remains debatable. Drs Harrington, Batchelor, and O'Donoghue discuss some of the data from TCT and predict the demise of bare metal stents.
  • When to Stent in Stable CAD? That Is (Still) the Question   Drs Harrington, Maron, and Patel discuss the ORBITA trial, which compared coronary stenting with sham percutaneous coronary intervention for angina relief. Why did ORBITA cause so much buzz?
  • AHAHOPE-Duchenne and Help at Last The final day of AHA 2017 brought Dr Walton Shirley to tears with studies offering hope to ease the suffering she has witnessed firsthand.
  • AHATrials We Did, Trials We Should Do Dr Walton-Shirley reflects on some major studies presented at AHA 2017 and offers a further way to approach each one.
  • Revascularization in CS: Keep It Simple and Get Out of Dodge   Drs Harrington, Batchelor, and O'Donoghue discuss the implications of the TCT late-breaking CULPRIT SHOCK trial testing culprit-only vs multivessel revascularization in unstable patients in cardiogenic shock.
  • TCTSeven Reasons New Data on Watchman Are Not Persuasive PREVAIL 5-year data and a patient-level meta-analysis nudge the Watchman left atrial appendage device to meeting noninferiority, but the devil is in the details, notes Dr Mandrola.
  • AHAMandrola Previews AHA 2017 The American Heart Association Scientific Sessions begin in Anaheim November 11. Learn which updates Dr Mandrola is most looking forward to.
  • Celebrities at Conferences: A Welcome Distraction? Medical meetings often host famous speakers, but Tom Hanks's appearance at a recent cardiology conference was for entertainment purposes only.